Antifungal therapy shows potential for IBD patients with Candida overgrowth

A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study by Weill Cornell Medicine investigators. The study, published in Nature Medicine, provides what is thought to be the first evidence that targeting intestinal fungal dysbiosis can reshape bacterial and fungal microbiome dynamics in patients with IBD and establishes a framework for mycobiome-guided precision therapies.

Read it at Medical Xpress ↗

← Front page